Mark Wechsler, MD
Anesthesiology · Weymouth, MANPI 1245407378
Payments from drug & device makers
Across 83 payments — averaging $63.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Braeburn Inc.$3K
- Relievant Medsystems, Inc.$612
- Boston Scientific$421
- Abbott$227
- Medtronic$206
- Vertos Medical, Inc.$182
- plus $736 from 15 others
What the payments were for
- Speaking & faculty fees$1,80034%
- Travel & lodging$1,01619%
- Food & beverage$2,46547%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Braeburn Inc. | 11 | $2,897 |
| Relievant Medsystems, Inc. | 8 | $612 |
| Boston Scientific | 16 | $421 |
| Abbott | 9 | $227 |
| Medtronic(2 entities) | 4 | $206 |
| Vertos Medical, Inc. | 5 | $182 |
| AbbVie | 6 | $149 |
| Zimmer Biomet | 3 | $121 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $77 |
| Nevro Corp. | 3 | $69 |
| Stryker | 1 | $50 |
| Biotronik NRO, Inc. | 1 | $41 |
| Biohaven Pharmaceuticals, Inc. | 2 | $34 |
| Pfizer | 2 | $31 |
| Bioventus LLC | 1 | $28 |
| Amgen | 1 | $24 |
| Saluda Medical Americas, Inc. | 1 | $24 |
| Baudax Bio Inc. | 1 | $23 |
| Si-bone, Inc. | 2 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Avanos Medical | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRIXADI$2,582
- Intracept$1,562
- mild Device Kit$101
How this compares
$5,281 in reported general payments places this provider in the 90th percentile of 1,585 anesthesiology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Baclofen | 17 | $643 |
| Cyclobenzaprine Hcl | 42 | $503 |
| Tizanidine Hcl | 13 | $325 |
| Etodolac | 19 | $283 |
| Pregabalin | 17 | $171 |
| Gabapentin | 15 | $107 |
| Methylprednisolone | 14 | $79 |
Paid to pharmacies, not to this prescriber.
Other anesthesiology in Weymouth
- Xiaodong BaoMethuen$1.4M
- Balachundhar SubramaniamLexington$747K
- Srdjan NedeljkovicBrighton$702K
- Mathias EikermannBoston$461K
- Robert YongBoston$459K
- Lorenzo BerraBoston$437K
- Timothy DelsolBoston$389K
- James StreisandCambridge$380K
- Edgar RossBoston$377K
- Hisham ElkadiMelrose$375K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.